Lexeo Therapeutics (LXEO) Competitors $3.89 -0.07 (-1.77%) Closing price 04:00 PM EasternExtended Trading$3.88 -0.01 (-0.13%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO vs. DNA, TYRA, PGEN, ARVN, TBPH, SAGE, ORGO, TSHA, ABVX, and BCYCShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Ginkgo Bioworks (DNA), Tyra Biosciences (TYRA), Precigen (PGEN), Arvinas (ARVN), Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Organogenesis (ORGO), Taysha Gene Therapies (TSHA), Abivax (ABVX), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Its Competitors Ginkgo Bioworks Tyra Biosciences Precigen Arvinas Theravance Biopharma Sage Therapeutics Organogenesis Taysha Gene Therapies Abivax Bicycle Therapeutics Lexeo Therapeutics (NASDAQ:LXEO) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Which has stronger valuation and earnings, LXEO or DNA? Lexeo Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo TherapeuticsN/AN/A-$98.33M-$3.30-1.18Ginkgo Bioworks$227.04M3.45-$547.03M-$9.16-1.46 Which has more risk & volatility, LXEO or DNA? Lexeo Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Does the media refer more to LXEO or DNA? In the previous week, Ginkgo Bioworks had 4 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for Ginkgo Bioworks and 1 mentions for Lexeo Therapeutics. Ginkgo Bioworks' average media sentiment score of 0.48 beat Lexeo Therapeutics' score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend LXEO or DNA? Lexeo Therapeutics presently has a consensus target price of $16.60, suggesting a potential upside of 326.74%. Ginkgo Bioworks has a consensus target price of $8.50, suggesting a potential downside of 36.48%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Lexeo Therapeutics is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is LXEO or DNA more profitable? Lexeo Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -198.84%. Ginkgo Bioworks' return on equity of -52.35% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -85.86% -68.48% Ginkgo Bioworks -198.84%-52.35%-27.14% Do institutionals & insiders believe in LXEO or DNA? 60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryGinkgo Bioworks beats Lexeo Therapeutics on 8 of the 15 factors compared between the two stocks. Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.14M$2.50B$5.58B$9.41BDividend YieldN/A1.81%4.00%4.03%P/E Ratio-1.188.8628.3219.89Price / SalesN/A722.23445.81100.95Price / CashN/A22.4924.9928.17Price / Book1.105.068.325.73Net Income-$98.33M$30.99M$3.24B$258.18M7 Day Performance-5.58%4.19%4.20%3.92%1 Month Performance-0.51%11.77%10.16%14.31%1 Year Performance-66.29%-1.57%34.69%17.29% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics1.6986 of 5 stars$3.89-1.8%$16.60+326.7%-64.6%$129.14MN/A-1.1858DNAGinkgo Bioworks0.6877 of 5 stars$9.91-0.7%$8.50-14.3%N/A$580.29M$237.42M-1.08640News CoverageTYRATyra Biosciences3.1138 of 5 stars$10.91+6.3%$30.83+182.6%-46.2%$579.21MN/A-6.6920PGENPrecigen4.0752 of 5 stars$1.95+6.6%$6.00+207.7%N/A$575.60M$4.20M-3.48190Positive NewsGap DownARVNArvinas3.9106 of 5 stars$7.87+1.0%$20.29+157.8%-73.6%$574.43M$263.40M-11.92420Upcoming EarningsTBPHTheravance Biopharma1.5771 of 5 stars$11.47+1.5%$16.60+44.7%+18.6%$573.50M$64.38M-9.72110SAGESage Therapeutics3.3969 of 5 stars$9.15-1.3%$8.75-4.4%-27.0%$572.97M$41.24M-1.58690ORGOOrganogenesis4.5001 of 5 stars$4.49+4.4%$6.00+33.6%+57.2%$569.56M$482.04M-26.41950TSHATaysha Gene Therapies4.006 of 5 stars$2.64flat$8.17+209.3%+18.2%$566.70M$8.33M-7.76180ABVXAbivax2.6877 of 5 stars$8.83+6.8%$31.00+251.1%-18.2%$560.44MN/A0.0061News CoveragePositive NewsGap UpTrading HaltedHigh Trading VolumeBCYCBicycle Therapeutics3.8628 of 5 stars$8.08+1.0%$25.00+209.4%-62.8%$559.54M$35.28M-2.57240 Related Companies and Tools Related Companies Ginkgo Bioworks Competitors Tyra Biosciences Competitors Precigen Competitors Arvinas Competitors Theravance Biopharma Competitors Sage Therapeutics Competitors Organogenesis Competitors Taysha Gene Therapies Competitors Abivax Competitors Bicycle Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXEO) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
